Latigo Biotherapeutics Inc. Common Stock

LTGO· NASDAQ· Health Care

$16.00+8.18%

2026-10-09

Valuation Metrics

Latigo Biotherapeutics Inc. Common Stock's Market Cap is $962M. Ranked #2459 of 3,115 in US market (top 79%), #1007 of 1,464 on NASDAQ (top 69%) by Market Cap.

Investment Metrics(as of 2026-10-09)

Metric	Value	Rank
Size
Market Cap	$962M	US#2,459/3,115
Employees	59	US#2,686/3,115
Performance
1M Return	-29.82%	US#3,045/3,115
From 52W High	-38.30%	US#2,397/3,115
1Y MDD	-40.84%	US#1,871/3,115
Trading
Volume	175,896 shares	US#2,527/3,115
Trading Value	$3M	US#2,726/3,115

Company Info

CEO Nima Farzan

Employees 59

HQ Thousand Oak, US

Website http://www.latigobio.com

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.